MADISON, WI (WTAQ) — Wisconsin has received its first allocation of oral antiviral COVID-19 treatments to treat patients diagnosed with mild to moderate COVID-19.
DHS says the initial supply of Pfizer’s Paxlovid and Merck’s molnupiravir is limited and a prescription is required.
Wisconsin’s first week allocation from the federal government includes 940 courses of Paxlovid and 4,320 courses of molnupiravir.
DHS will distribute the courses to select pharmacies by Friday.
